Precigen (PGEN) News Today

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a b

Sanders Morris Harris LLC acquired a new position in Precigen, Inc. (NASDAQ:PGEN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 705,000 shares of the biotechnology company's stock, valued at

MSD Partners L.P. trimmed its stake in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) by 63.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 355,000 shares of the biotechnology company's stock

Patient Capital Management LLC lifted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN - Free Report) by 16.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,983,700 shares of the biotechnology company'

JMP Securities reiterated a "market outperform" rating and issued a $14.00 price objective on shares of Precigen in a research note on Tuesday.

Stifel Nicolaus increased their price target on Precigen from $7.00 to $10.00 and gave the company a "buy" rating in a report on Monday.

HC Wainwright reissued a "buy" rating and set a $6.00 price target on shares of Precigen in a report on Monday.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Cantor Fitzgerald dropped their FY2024 earnings estimates for shares of Precigen in a report released on Wednesday, May 15th. Cantor Fitzgerald analyst J. Kim now expects that the biotechnology company will post earnings of ($0.36) per share for the ye

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 earnings estimates for Precigen in a research report issued on Wednesday, May 15th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.

Precigen (NASDAQ:PGEN - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). Precigen had a negative net margin of 1,540.63% and a negative return on equity of 55.47%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter last year, the firm posted ($0.10) EPS.

Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the four brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and three have given a buy rating t

Cantor Fitzgerald reiterated an "overweight" rating on shares of Precigen in a report on Wednesday.

Precigen (NASDAQ:PGEN) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports.

JPMorgan Chase & Co. cut shares of Precigen from a "neutral" rating to an "underweight" rating in a report on Friday.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2024 earnings per share (EPS) estimates for Precigen in a note issued to investors on Wednesday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will

JMP Securities reaffirmed a "market outperform" rating and set a $14.00 target price on shares of Precigen in a research note on Wednesday.